Business Context and Reporting Period
This Form 8-K Current Report is filed by Novavax, Inc. for the event date of October 31, 2018. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments rather than financial performance.
- Director Compensation: Annual retainer of $40,000.
- Equity Grant: Stock option award of 160,000 shares of common stock.
Material Changes
The material change reported is the appointment of Rachel K. King to fill an existing vacancy on the Board of Directors. She was appointed as a Class III director, with a term expiring at the 2019 annual meeting of stockholders. No Board committee assignments were made at the time of this filing.
Outlook, Risks, and Management Commentary
The Board has affirmatively determined that Ms. King is independent and has no material direct or indirect interest in a related party transaction requiring disclosure. An indemnification agreement was entered into to provide protection for Ms. King in connection with her service. The filing incorporates a press release dated November 1, 2018, regarding this appointment.
Investor Verification Checklist
- Verify the independence status of the newly appointed director, Rachel K. King.
- Review the terms of the stock option award (160,000 shares) under the Amended and Restated 2015 Stock Incentive Plan.
- Confirm the expiration date of the director's term (2019 annual meeting).
- Check for any subsequent committee assignments not listed in this initial filing.